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Abstract
Background: One of the most frequently used and efficient suicide gene therapies for prostate cancer is HSV-TK/
GCV system, but its application has been limited due to lack of favorable gene vector and the reduction of
“bystander effect”. We investigated the effect of a novel combination of HSV-TK/GCV fused with Cx43 and
gemcitabine using non-viral vector generation 5 polyamidoamine dendrimers (G5-PAMAM-D) on PC-3 cells.
Methods: RT-PCR and Western blot were used to detect TK and Cx43 expression. Cell viability and proliferation
were measured by using MTT assay. Cell apoptosis was detected with double-staining of Annexin V-FITC and
propidium iodide (PI) by flow cytometry. Nude mice models were established to evaluate the therapeutic effect in
vivo.
Results: G5-PAMAM-D efficiently delivered recombinant plasmids into PC-3 cells and HSV-TK and Cx43 could be
expressed successfully. With gemcitabine, G5-PAMAM-D mediated HSV-TK and Cx43 expression effectively inhibited
prostate cancer PC-3 cell proliferation, leading to more cellular apoptosis and inhibiting PC-3 tumor growth in
nude mice models.
Conclusions: This study illustrates that this new suicide gene system mediated by G5-PAMAM-D is effective in
decreasing PC-3 cell proliferation and inducing cell apoptosis, and inhibiting tumor growth in vivo. In a word, our
study could provide a potential approach for gene therapy of prostate cancer.
Background
The incidence and mortality of prostate cancer are gradu-
ally increasing in the world in recent years [1]. Localized
prostate cancer can be managed effectively with surgery or
radiation [2]. However, tumor progression is eventually
inevitable after hormonal deprivation therapy for most
patients [3]. There are no curable approaches for prostate
cancer in an androgen independent state [4]. For this rea-
son, it is necessary to search for new and effective therapy.
Gene therapy is a hopeful therapeutic approach for pros-
tate cancer [5]. While suicide gene therapy is an attractive
approach, in which a gene encoding for a metabolic
enzyme that can convert a nontoxic prodrug into a toxic
compound is introducted into tumor cells. The nontoxic
prodrug can be given at high doses to maintain appropri-
ate treatment in tumor cells, without negative effects to
the normal cells. It is considered that suicide gene therapy
is the focus of the cancer gene therapy research because of
its “bystander effect” [6]. The “bystander effect” is a phe-
nomenon that the transduction of a small fraction of
tumor cells with the suicide gene can result in widespread
tumor cell death. It can compensate for the lowered effi-
cacy of vectors and accomplish complete killing of a
tumor. The most frequently used suicide gene therapy for
prostate cancer is Herpes Simplex Virus Thymidine
Kinase (HSV-TK)/ganciclovir (GCV) system [7,8]. How-
ever, the reduction of “bystander effect” and the safety
problems of viral vectors need to be solved urgently.
Adenovirus vectors are the most common viral vectors
used for anti-cancer therapy in human clinical studies [9].
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transfer efficiency, the major disadvantage of these vectors
is immunogenicity. That is to say, immune responses
probably induced by the repeat application of adenoviral
vectors may result in the removal of vectors in human
body. Generation 5 polyamidoamine dendrimers (G5-
PAMAM-D) is a kind of new synthetic nanoparticles poly-
mer material. Compared with viral vectors, its advantages
lie within its non-toxic and non-immunogenic nature, in
addition to its capability to carry larger pieces of DNA.
Study has indicated that “bystander effect” is essential in
suicide gene therapy [10]. Increasing the density of gap
junctions can enhance the “bystander effect” by expression
of connexin 43 (Cx43) [11]. When gemcitabine were used
for HSV-TK/GCV suicide gene therapy of glioma, the
“bystander effect” was significantly enhanced [12]. In this
study, we will explore the effect of expression of Cx43 and
gemcitabine in suicide gene therapy for prostate cancer.
Methods
Cell culture and animals
Human prostate cancer PC-3 cells were obtained from
our TianJin Institute of Urology. PC-3 cells were main-
tained at 37°C in a humidified atmosphere of 5% CO2 in
RPMI1640 medium (Gibco, USA), supplemented with
10% fetal bovine serum (FBS) (Gibco, Uruguay), penicillin
(100 U/ml) and streptomycin (100 μg/ml). Six-week-old
male BALB/c nude mice (Animal Resources Centre,
Military Medical Sciences, BeiJing, China) were used for
the experiments. Mice were maintained under specific
pathogen-free, temperature-controlled conditions at the
animal facilities of College of Life Science in Naikai
University. Mice were handled in accordance with Insti-
tutional Animal Welfare Guidelines.
Vectors and plasmids
G5-PAMAM-D is synthesized and kindly provided by
Key Laboratory of Bioactive Materials of Ministry of
Education of Nankai University [13]. Plasmid pCMV-
TK-Cx43 and pCMV-TK had been successfully con-
structed in our laboratory. Cx43 gene was amplified by
PCR from HL60 genomic DNA and subcloned into
pMD19-T Simple vector, which was digested by Sal I
and Not I, named pMD-Cx43. TK gene was synthesized
from pORF-HSV-TK (TakaRa, China) and was inserted
into pMD19-T Simple vector with Xho I and Mlu I,
producing pMD-TK. Then the pIRES and pMD-TK
plasmids were degested by Xho I and Mlu I and TK
fragment was cloned into multiple clone site (MCS) A
of pIRES to generate the pCMV-TK. The pCMV-TK
and pMD-Cx43 plasmids were digested by Sal I and Not
I. Then the Cx43 fragment was inserted into MCS B of
pCMV-TK plasmid. The new plasmid was named
pCMV-TK-Cx43. Escherichia coli strain DH5a carrying
recombinant plasmids were shaking cultured in LB med-
ium (250 ml) containing ampicillin (100 μg/ml) at 37°C
for 16-18 h. Two plasmids were extracted using Plasmid
Purification Maxi Kits (QIAGEN, China).
Cell transfection
PC-3 cells were plated until they reached 70-80% con-
fluency, then different mixtures (G5-PAMAM-D mixed
with two different plasmids at a 1:3 molar ratio respec-
tively) were added gently to cells covered with serum-free
medium. All the cells were divided into 7 groups: Group
A, B (G5-PAMAM-D/pCMV-TK-Cx43); Group C, D (G5-
PAMAM-D/pCMV-TK); Group E (G5-PAMAM-D);
Group F (pCMV-TK-Cx43); Group G (neither vector nor
plasmid). Gemcitabine would be added to group A, C and
F when MTT assay and apoptosis detection were con-
ducted. After incubation for 6 h at 37°C, the medium was
replaced with fresh serum-containing medium. After 48 h
of incubation, cells were used for different experiments.
RT-PCR analysis
Total cell RNAs were isolated 48 h after transfection
using Multisource Total RNA Miniprep Kit (AXYGEN,
China). The synthesis of cDNA and PCR were performed
using one-step RT-PCR system (TransGen Biotech Co.
Ltd, Beijing, China). PCR was run in a 50 μl reaction
volume. The PCR specific primer pairs (TaKaRa, China)
were 5’-CCGCTCGAGATGGCCTCGTACCCCGGC-
CATCAACA-3’(forward) and 5’-CGAAAGCTTACCA-
GAACCACCGTTAGCCTCCCCCATCTCCCGGGCA-3’
(reverse) for analysis of TK, 5’-GTCGACATGGGT-
GACTGG AGCGCCTT-3’ (forward) and 5’-GCGGCCG
CCTAGATCTCCAGGTCATCAGG-3’(reverse) for ana-
lysis of Cx43. The amplified product of TK had 1143 bp
and that of Cx43 had 1149 bp. The PCR products
o fT Ka n dC x 4 3w e r ea n a l y z e db y0 . 8 %a g a r o s eg e l
electrophoresis.
Western blot analysis
48 h after transfection, cells were rinsed twice with cold
PBS, then homogenized in RIPA cell lysate and centri-
fuged. The protein concentration of each sample was
quantified by the Bradford assay. Fifty micrograms of total
cell extract protein was separated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred onto polyvinylidene difluoride (PVDF)
membrane. After being blocked with 5% skimmed milk
for 1 h at room temperature, the membrane was incubated
with goat anti-TK (Santa Cruz Biotechnology, CA, USA)
or rabbit anti-Cx43 (Abcam, Cambridge, MA) antibody
overnight at 4°C. After extensive washes, blots were incu-
bated with the dilution (1:2000) horseradish peroxidase
conjugated anti-goat or anti-rabbit IgG (Santa Cruz Bio-
technology, CA, USA) for 90 minutes at 37°C. The bands
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GAPDH (Santa Cruz Biotechnology, CA, USA) was used
as an internal control.
Cell proliferation assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbro-
mide (MTT), GCV, gemcitabine were all purchased from
Sigma (USA). 48 h after transfection, 200 μlo ft h ec o m -
plete medium was replaced with that containing different
concentrations of GCV (0.1, 1, 5, 0, 20, 50, 100, 200,
500 μg/ml) and gemcitabine (500 μmol/l) was added to
Group A, C and F at the same time. After incubation for
6h( i n5 %C O 2 at 37°C), fresh complete medium was
replaced. Then 20 μl of 5 mg/ml MTT solution was added
to each well. After 4 h of incubation at 37°C, the superna-
tant was removed and 150 μl of DMSO were added to
each well. The absorbance of optical density at 570 nm
(A570) was measured using a Microplate Reader.
Cell growth inhibition rate was calculated according to the
formula (A570 of control cells-A570 of treated cells) ×
100%/A570 of control cells and the curve was drawn.
Detection of cell apoptosis
The detection of cell apoptosis was performed according
to the instructions of Annexin V-FITC apoptosis kit
(Beckman Coulter, CA, USA). 48 h after transfection,
200 μl of the complete medium containing GCV (50 μg/
ml) was administrated and gemcitabine (500 μmol/l) was
added to Group A, C and F at the same time. After incu-
bation for 6 h, cells were centrifuged and resuspended
with cold binding buffer at concentration 1.0 × 10
6/ml.
100 μl of the cell suspension was added to 5 ml flow pipe
mixed with 5 μl Annexin V-FITC and 10 μl PI. After dark
incubation for 15 minutes at room temperature, flow cyto-
metry was used to detect apoptotic cells.
In vivo antitumoral activity
A suspension of PC-3 cells (4 × 10
6 cells) in 200 μl of mix-
ture containing PBS and Matrigel matrix basement mem-
berane (BD Corporation, USA) at 3:1 ratio of volume was
injected subcutaneously into the right armpit regions
of mice. When the tumor volume reached approximately
0.1 cm
3, usually ten days after cell implantation, the mice
were randomly divided into eight groups (five animals per
group). The mice were submitted to intratumoral injection
three times (day1, 7 and 13) with the mixture of G5-
PAMAM-D/pCMV-TK-Cx43(Group I and II), the mixture
of G5-PAMAM-D/pCMV-TK(Group III and IV), the mix-
ture of G5-PAMAM-D (Group V), the mixture of pCMV-
TK-Cx43 (Group VI), PBS (Group VII) and no treatment
(Group VIII). 24 hours after the injections of mixtures
every time, GCV (100 mg/kg) was administered intraperi-
tonial once a day for 5 consecutive days. Gemcitabine
(20 mg/kg) was administrated intraperitonial in Group I,
III and VI at day 2, 8 and 14 respectively. The tumor
volume was calculated at regular intervals according to the
formula V = π/6 × length × width
2. After mice were sacri-
ficed, tumors were extracted and weighted. Tumor speci-
mens were used for histological analysis.
Statistical analysis
Statistical analysis was performed using SPSS software
(version 13.0). The significance of differences between
multiple groups was determined by one-way analysis of
variance followed by the LSD test. Data was expressed as
means ± standard deviation. Statistical significance was set
at P < 0.05.
Results
Expressions of TK and Cx43 after PC-3 cells transfection
To evaluate whether recombinant plasmids can be success-
fully transferred into PC-3 cells by using G5-PAMAM-D,
and whether TK and Cx43 genes can be expressed, total
PC-3 cell RNAs and cell proteins were extracted from dif-
ferent groups after transfection. The expressions of TK and
Cx43 were detected by RT-PCR and Western blot. As
shown in Figure 1, TK was expressed in Group A to D and
Cx43 was expressed in Group A and B. Neither TK nor
Cx43 was expressed in Group E to G.
Double-enhanced suicide gene system suppresses PC-3
cell growth
To investigate the effect induced by this new suicide gene
system, the level of cell proliferation was assessed by the
MTT assay. As shown in the cell growth inhibition rate
curve (Figure 2), cell growth inhibition rates of Group A
to D gradually increased in different extent with the
increasing concentrations of GCV, and the cell growth
inhibition rate of Group A was much higher than other
groups under the same experimental conditions (P < 0.01).
Cell proliferations almost were not influenced in Group F
at different GCV concentrations. In addition, the cell
growth inhibition rate of Group E stayed at much lower
level than those of Group A to D (P < 0.01).
Double-enhanced suicide gene system induces apoptosis
in PC-3 cells
Based on staining the cells with Annexin V-FITC and PI,
flow cytometry was used to quantify the extent of apopto-
sis. The points of lower right quadrant in Figure 3A are on
behalf of apoptotic cells. As demonstrated in Figure 3B,
the maximal apoptosis rate of Group A was 12.51% (12.37
± 0.17), only 80% of the living cells remaining, which was
significantly higher than the other groups (P < 0.01). The
apoptosis rates of Group F and G were much lower than
other groups (P < 0.01), the highest apoptosis rate in
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was only 1.44% (1.14 ± 0.25), with no difference between
these two groups (P > 0.05). The cell apoptosis rates of
Group B-D were significantly higher than those in Group
E to G (P < 0.01). And the cell apoptosis rate of Group E
was higher than those of Group F and G (P < 0.01).
Figure 2 Cell growth inhibition rate curve. Cell growth inhibition rate curves were drawn to evaluate cell growth according to MTT assay. The
results showed different growth inhibition rates of PC-3 cells in all groups. The Group A had an obviously higher growth inhibition rate than
other groups (P < 0.01).
Figure 1 Expressions of TK and Cx43 after PC-3 cells transfection. A. The TK bands of 1143 bp were detected in Group A, B, C, D and the
Cx43 bands of 1149 bp were only detected in Group A and B. B. The TK proteins were detected in Group A, B, C, D and the Cx43 proteins
were only detected in Group A and B. Equal loading was confirmed by stripping the blot and reprobing it for GAPDH.
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tumor growth in vivo
To evaluate the effects of the suicide gene system on the
PC-3 tumor growth in animal mode, the tumor volume
and tumor weight were measured. Average tumor
volumes were similar in all mice before therapy. All mice
survived during the period of treatment. We found from
Figure 4A that average tumor volumes of all groups had
no significant difference during the first two days after
treatment (P > 0.05). The average tumor volumes of
Group I to IV were significantly smaller than other four
groups (P < 0.01), and that of Group I was the smallest
(P < 0.01). The average tumor volume of Group I
reduced by about 70% after initiation of treatment com-
pared with Group VIII. Average tumor volumes of Group
V to VIII had no difference during the whole procedure
(P > 0.05). As shown in Figure 4B, the final tumor
weights of Group I to IV were significantly decreased
Figure 3 Analysis of PC-3 cells apoptosis. A. Flow cytometric detection of PC-3 cell apoptosis. The points of lower right quadrant represent
apoptotic cells, and the points of upper right quadrant are on behalf of necrotic cells. The apoptosis rate of Group A was 12.38%, which was
higher than those of the other groups. B. The average apoptosis rates of all 7 groups are shown in the bar chart. Higher percentage of
apoptosis cells were detected by Annexin V-FITC and PI staining in Group A than in other groups. ** indicates P < 0.01 when compared to
Group A.
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significant difference among these four groups compar-
ing with each other (P < 0.05). The average tumor weight
of Group I was the lightest in all groups (P < 0.01). The
final tumor weight had no difference in Group V to VIII
(P > 0.05). Specimens histological analysis was performed
after tumors were isolated. The results shown in Figure 5
illustrated that there were extensive areas of coagulation
necrosis and hemorrhage with leukocyte infiltration in
the tumors from Group I to IV. On the other hand, any
significant necrotic and hemorrhagic areas or leukocyte
infiltration were not found in Group V to VIII.
Discussion
One of the most frequently used and efficient suicide
gene therapy approaches in cancer treatment is HSV-
TK/GCV system [14]. There were a lot of researches
about the HSV-TK/GCV suicide gene therapy of pros-
tate cancer [11,15,16]. We have illustrated that HSV-
TK/GCV system played a role in inhibiting the prolifera-
tion of PC-3 cells in vitro and in vivo. However, the pri-
mary problem that restricted the application of suicide
gene therapy for prostate cancer is lack of suitable vec-
tor. Nowadays the studies about non-viral vectors are
gradually increasing, such as liposomes, chitosan, poly-
ethylene imine (PEI), polylysine (PLL), etc. PAMAM-D
has its unique physical and chemical characteristics and
advantages, which can provide favorable conditions for
its application [13,17,18]. In our study, successful
expression of TK and Cx43 in PC-3 cells transfected via
G5-PAMAM-D was confirmed by RT-PCR and Western
blot. This result indicated that G5-PAMAM-D as a gene
vector could deliver recombinant plasmids into PC-3
cells successfully.
Figure 4 Inhibition of tumor growth in nude mice model. A. Tumor volumes were measured every 2 days after the first injection. The
average calculated tumor volumes are shown for the indicated time points. The average tumor volumes of Group I to IV were smaller than
other four groups (P < 0.01). The average tumor volume of Group I was the smallest than other groups (P < 0.01). No significant difference in
average tumor volumes of Group V to VIII was seen during the whole procedure (P > 0.05). B. The bar chart shows the average tumor weights
of all 8 groups. The average tumor weight of Group I was the lightest. * indicates P < 0.05, ** indicates P < 0.01 when compared to Group I.
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was the"bystander effect”, by which a high percentage of
tumor cell death can occur, even when a low percentage
of cells was transfected [19]. Suicide gene therapy
became more effective when"bystander effect"enhanced
[10]. Furthermore, it is believed that gap junctional
intercellular communication via connexin (Cx) played a
vital role in the “bystander effect” mediated by HSV-
TK/GCV system [20]. Cx gene was considered as a non-
mutant tumor suppressor gene, and it played a negative
regulation role in the growth of most tumor cells
including prostate cancer cells [21]. Cx43 is a gap junc-
tion protein containing 378 amino acids and its molecu-
lar weight is 43 kDa. Tumor progression and metastasis
are correlated with reduction or absence of Cx43 gene
expression [22]. It is reported that down-regulated
expression of connexin play an important role in carci-
nogenesis and the “bystander effect” mediated by HSV-
TK/GCV gene therapy [20]. Gemcitabine is a kind of
deoxycytidine analogue and it can kill tumor cells by
blocking DNA synthesis in tumor cells. Some scholars
used gene therapy combining with gemcitabine for pan-
creatic cancer and glioma, and found the"bystander
effect"significantly enhanced [23,24]. In our experiment,
PC-3 cell growth was inhibited in Cx43-expressing cells
comparing with the cells transfected with no Cx43.
These results illustrated Cx43 played a role in enhancing
the"bystander effect"and inhibiting cell proliferation. On
the other hand, the cell growth inhibition rates and
apoptosis rates in the cells treated with gemcitabine
were significantly higher. These results illustrated that
gemcitabine enhanced the"bystander effect"and inhibited
PC-3 cells growth.
In line with the studies in vitro, we established pros-
tate cancer nude mice model with PC-3 cells. After dif-
ferent experimental intervention, the status of tumor
growth was observed. The results demonstrated that
tumor growth was significantly inhibited by double-
enhanced suicide gene system. Histological analysis
showed that tumor tissues were damaged after adminis-
tration of treatment system in our study visually. These
experimental results in vivo suggested the system played
a significant role of suppressing tumor progression.
In a word, our study implied that expression of Cx43
and gemcitabine could enhance the “bystander effect” of
HSV-TK/GCV gene therapy. This double-enhanced sui-
cide gene system was effective in inducing cell growth
inhibition and apoptosis in vitro and suppressing tumor
growth in vivo. It may be a potential approach for gene
therapy of prostate cancer and could provide a choice to
attempt suicide gene therapy for locally advanced or
metastatic prostate cancer. Nonetheless, the effect of
this therapy system on prostate cancer needs to be veri-
fied in other prostate cancer cell lines. In addition, we
will also investigate the inhibitory effects of this system
on tumor model in situ. This system will stand a good
chance to be used for improving prostate cancer treat-
ment combined with other therapies.
Conclusions
This study illustrates that this new suicide gene system
mediated by G5-PAMAM-D is effective in decreasing
Figure 5 Histological analysis of tumor specimen. Hematoxylin and eosin staining (magnification × 100) in excised tumor tissues were
conducted after treatment with different mixtures by intratumoral injection. Cell necrosis and hemorrhage with leukocyte infiltration in the
tumors were observed from Group I to IV. No obvious pathological changes were shown from Group V to VIII.
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inhibiting tumor growth in vivo.
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